Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.

Sano R, Krytska K, Larmour CE, Raman P, Martinez D, Ligon GF, Lillquist JS, Cucchi U, Orsini P, Rizzi S, Pawel BR, Alvarado D, Mossé YP.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaau9732. doi: 10.1126/scitranslmed.aau9732.

PMID:
30867324
2.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
3.

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.

Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, Grandinetti KB, Tuntland T, Kim S, Caponigro G, He YQ, Krupa S, Li N, Harris JL, Mossé YP.

Clin Cancer Res. 2017 Jun 1;23(11):2856-2868. doi: 10.1158/1078-0432.CCR-16-1114. Epub 2016 Dec 16.

4.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC.

Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.

5.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP.

Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.

6.

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.

Krytska K, Ryles HT, Sano R, Raman P, Infarinato NR, Hansel TD, Makena MR, Song MM, Reynolds CP, Mossé YP.

Clin Cancer Res. 2016 Feb 15;22(4):948-60. doi: 10.1158/1078-0432.CCR-15-0379. Epub 2015 Oct 5.

7.

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP.

Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10.

8.

Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells.

Carpenter EL, Rader J, Ruden J, Rappaport EF, Hunter KN, Hallberg PL, Krytska K, O'Dwyer PJ, Mosse YP.

Front Oncol. 2014 Jul 31;4:201. doi: 10.3389/fonc.2014.00201. eCollection 2014.

9.

Cytokines alter glucocorticoid receptor phosphorylation in airway cells: role of phosphatases.

Bouazza B, Krytska K, Debba-Pavard M, Amrani Y, Honkanen RE, Tran J, Tliba O.

Am J Respir Cell Mol Biol. 2012 Oct;47(4):464-73. doi: 10.1165/rcmb.2011-0364OC. Epub 2012 May 16.

10.

Surfactant protein D inhibits TNF-alpha production by macrophages and dendritic cells in mice.

Hortobágyi L, Kierstein S, Krytska K, Zhu X, Das AM, Poulain F, Haczku A.

J Allergy Clin Immunol. 2008 Sep;122(3):521-528. doi: 10.1016/j.jaci.2008.05.002. Epub 2008 Jun 12.

11.

Ozone inhalation induces exacerbation of eosinophilic airway inflammation and hyperresponsiveness in allergen-sensitized mice.

Kierstein S, Krytska K, Sharma S, Amrani Y, Salmon M, Panettieri RA Jr, Zangrilli J, Haczku A.

Allergy. 2008 Apr;63(4):438-46. doi: 10.1111/j.1398-9995.2007.01587.x.

PMID:
18315731

Supplemental Content

Loading ...
Support Center